Entries by

, ,

AJRCCM publishes MV130 study

AJRCCM publishes in its August issue the results of the efficacy of MV130 in the prevention of recurrent wheezing attacks in young children. This is a randomized, double-blind, placebo-controlled phase 3 clinical trial conducted in two hospitals in Spain. The results are highlighted in an Editorial, which points out its importance as a new therapeutic option for the prevention of these processes and the implication of innate immune training as a possible mechanism of action.

,

Allergoids coupled to mannan reprogram human monocytes

The Journal of Allergy and Clinical Immunology publishes a study showing that mannan-allergoid conjugates reprogram human monocytes to facilitate their differentiation into tolerogenic dendritic cells. These results allow a better understanding of the cellular and molecular mechanisms of novel allergy vaccines based on these glycoconjugates.

,

MV130/MV140 in infections under immunosuppressive treatment

According to a study published in Frontiers in Immunology, MV130 (Bactek) and MV140 (Uromune) reduce respiratory and urinary tract infections, respectively, in patients with systemic autoimmune diseases under immunosuppressive therapy. The decrease in infections in patients treated with MV130/MV140 is associated with reduced antibiotic consumption, unscheduled hospital visits and hospitalizations.

,

JACI highlights results with MV130

The Journal of Allergy and Clinical Immunology highlights in its June issue, section “News Beyond Our Pages”, the results published in AJRCCM (American Journal of Respiratory and Critical Care Medicine) with MV130, a sublingual preparation developed and manufactured by INMUNOTEK. The study, conducted in young children with recurrent bronchiolitis, demonstrates the efficacy of bacterial immunotherapy with MV130 in the reduction and duration of these episodes.

,

Pollution, pollen and symptoms

The journal Environmental Science and Pollution Research has published a study on the influence of environmental pollution in the city of Madrid, levels of pollens and environmental allergens on the symptoms presented by patients allergic to grass pollen. The study has been developed over 18 months with the participation of different experts and the collaboration of INMUNOTEK.

INMUNOTEK at SPAP Digital 2021

INMUNOTEK has participated in the SPAP (Portuguese Society of Pediatric Allergology) Digital Congress with the presentation “Trained immunity vaccines (TIbV) through mucosa against viral infections: the MV130 model” by Dr. Laura Conejero Hall.

MV130 reduces wheezing attacks in young children

The journal ARJCCM publishes online a randomized clinical trial conducted with MV130 (Bactek) aimed at evaluating its effect on safety and efficacy in the prevention of recurrent viral wheezing attacks in young children. MV130 is a sublingual bacterial preparation produced by INMUNOTEK for non-specific mucosal immunotherapy in recurrent respiratory infections.

INMUNOTEK Symposium at the 42nd SEI Congress

Within the 42nd congress of the SEI (Spanish Society of Immunology) INMUNOTEK has organized a satellite symposium on trained immunity-based vaccines (TIbV) that act through mucosa and their potential role against respiratory infections of viral origin.

MV130 in B cell hematological malignancies

According to a study published in Frontiers in Immunology, MV130 (Bactek) prevents recurrent infections in patients with malignant B-cell diseases. Respiratory tract infections are very common in these patients and require prophylactic treatment with antibiotics, which are not useful in many infections and they are not without risk. MV130 is a sublingual vaccine framed in the new concept of TIbV (trained immunity-based vaccines) with a wide spectrum of action against different pathogens.